Therapeutic | Evolocumab |
Target | PCSK9 |
Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS |
Light Chain | ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | Abgenix XenoMouse |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Amgen%3BAmgen Astellas BioPharma%3BUniversity Hospital Inselspital |
Conditions Approved | Coronary disorders%3BHypercholesterolaemia%3BHyperlipoproteinaemia type IIa%3BMyocardial infarction%3BStroke |
Conditions Active | Hyperlipidaemia%3BCoronary artery disease%3BDyslipidaemias |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]